Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

What Factors Predict Permanent Pacemaker Implantation after TAVR? CONDUCT-TAVI Outcomes

Permanent pacemaker implantation (PPM) for high grade atrioventricular block (AVB) continues to be one of the most frequent complications after transcatheter aortic valve replacement (TAVR), with 10 to 15 % annual incidence. However, the available predictive algorithms still show limitations. 

The CONDUCT-TAVI, a prospective multicenter study carried out in two Australian centers, included 200 patients undergoing TAVR between 2021 and 2023. Baseline clinical anatomical and procedural variables were recorded, and an electrophysiology study was conducted measuring AH/HV intervals, and rapid atrial stimulation was used to determine the Wenckebach point (AVW). Also, subcutaneous loop recorders were implanted for continuous one-year rhythm monitoring. 

The primary end point was PPM implantation secondary to high grade AV block. Secondary end points included early (≤ 48 h) and late (> 48 h) PPM implantation, new persistent left bundle branch block (LBBB), and de novo atrial fibrillation (AF). 

Read also: Functional Assessment of Coronary Stenoses: Hyperemic, Non-Hyperemic, and Angiographic Alternative Indices.

At one year, total PPM incidence for high grade AV block was 21 % (13.5 % early and 7.5 % late), while de novo AF was observed in 21.7 % of patients. New-onset persistent left bundle branch block (immediately after) was 43.6 %, dropping to 19.1 % after 24 hours. Total mortality was 7.5%, and cardiovascular mortality was 2.5 %.

Independent predictors of PPM implantation were:

  • preexisting right bundle branch block (RBBB) (OR 5.45; CI 95 %: 1.67–17.84; p = 0.005), 
  • Increased interval (ΔHV) >10 ms (OR 3.62; CI 95 %: 1.23–10.67; p = 0.020), and 
  • Pre-TAVI Wenckebach (AVW) point induced by rapid atrial pacing (OR 3.70; 95% CI, 1.37-9.98; P=0.010).

The multivariable model integrated these variables into the CONDUCT-TAVI score, which reached an area under the curve (AUC) of 0.794 and a negative predictive value of 98 %.

Lea también: ¿Cuándo es el momento óptimo para el reemplazo valvular aórtico? Impacto del síndrome valvular agudo en los resultados y los costos.

The Cox analysis confirmed pre-TAVR RBBB and AVW were independent predictors of PPM at one year. Also, PPM risk was significantly higher with self-expanding valves (78.6 % vs. 57.0 %; p = 0.01), oversized devices relative to annuli (19.7 % vs. 14.8 %; p < 0.001) and transient intraprocedural AV block (54.8 % vs. 10.8 %; p < 0.001).

Conclusion

This prospective study confirms that conduction alterations continue to be frequent after TAVR with 21% incidence of PPM implantation for high grade AV block and 21.7 % of de novo AF. Electrophysiological factors resulted the most solid predictors, and the CONDUCT-TAVI score showed great capacity to identify low risk patients (negative predictive value 98 %), which might optimize followup and favor early discharge after procedure. 

Original Title: Prospective Observational Study on the Accuracy of Predictors of Permanent Pacemaker Secondary to High-Grade Atrioventricular Conduction Block After TAVI (CONDUCT-TAVI).

Reference: Karan Rao et al., Circulation: Cardiovascular Interventions, Vol. 18, e015446, 2025.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...